New Jersey's biopharmaceutical sector represents a critical part of healthcare innovation, hosting companies that specialize in research, development, and manufacturing. This industry focuses on tailored therapies ranging from vaccines to treatments for rare diseases, addressing pressing health challenges. With advanced biotech methodologies and a commitment to quality, New Jersey's firms contribute to significant breakthroughs in medicine. The ongoing evolution toward personalized medicine and biotechnological advancements promises an invigorating future, positioning the state as a pivotal hub for medical innovation and patient care on a global scale.

The listing includes 23 biopharmaceutical companies primarily located in New Jersey. These firms range from startups to established entities, showcasing employee counts that vary from small teams to several thousand. Founded primarily in the late 20th and early 21st century, each company boasts unique specializations, from plasma therapies at Kedrion to the novel oncology solutions from Elevar Therapeutics. This diversity illustrates New Jersey’s dynamic environment for biopharmaceutical advancement.

Continue reading to explore the top biopharmaceutical companies in New Jersey.

Top 23 Biopharmaceuticals Companies in New Jersey

1. Kedrion Biopharma

• Website: kedrion.com
• Ownership type: Private Equity
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, Other 11%
• Latest funding: September 2022
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: kedrion-biopharma

Kedrion Biopharma is a biopharmaceutical company based in Fort Lee, New Jersey, with a strong focus on plasma-derived therapies aimed at treating rare and debilitating conditions. Established in 2001, Kedrion has grown to employ over 2,200 individuals across various locations, including significant operations in Italy, the United States, and the United Kingdom. The company specializes in collecting and fractionating blood plasma to produce essential medical products that cater to conditions such as coagulation disorders and immunodeficiencies. Kedrion operates multiple production plants and plasma collection centers, ensuring a steady supply of their therapies to healthcare providers and national health systems worldwide. Their recent acquisition of Bio Products Laboratory (BPL) in 2022 has expanded their capabilities and product offerings, reinforcing their commitment to addressing the needs of patients with rare diseases. Kedrion's focus on quality, safety, and social responsibility underpins their operations, making them a notable player in the biopharmaceutical industry.

2. Eisai US

• Website: us.eisai.com
• Ownership type: Private
• Headquarters: Nutley, New Jersey, United States (USA)
• Employee distribution: United States (USA) 89%, Other 11%
• Founded year: 1995
• Headcount: 1001-5000
• LinkedIn: eisai

Eisai US, based in Nutley, New Jersey, is a pharmaceutical company that specializes in creating innovative medicines for oncology and neurology. Founded in 1995, the company operates with a workforce of approximately 2,955 employees. Eisai US is dedicated to addressing the needs of patients and healthcare providers through its extensive product offerings and ongoing clinical trials. Their commitment to human health care is evident in their active participation in community involvement and patient support initiatives. Eisai's product portfolio includes notable medications such as Leqembi for Alzheimer's disease and Lenvima for various cancers. The company also emphasizes corporate responsibility and has established programs to support patients and their families throughout their health journeys. With a focus on breakthrough solutions, Eisai US continues to contribute to the biopharmaceutical industry by tackling challenging diseases that require innovative approaches.

3. NPS Pharma

• Website: shire.com
• Ownership type: Corporate
• Headquarters: Bedminster, New Jersey, United States (USA)
• Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, Other 25%
• Latest funding: $86.4B, April 2018
• Founded year: 1986
• Headcount: 201-500
• LinkedIn: nps-pharmaceuticals

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, the company specializes in the research, development, manufacturing, and marketing of innovative medicines. NPS Pharma focuses on therapeutic areas that include gastrointestinal diseases, rare diseases, oncology, and vaccines. Their commitment to transforming lives is evident through their extensive product pipeline and ongoing clinical trials. With a workforce of approximately 148 employees, NPS Pharma plays a crucial role in Takeda's global strategy, contributing to the development of treatments that address unmet medical needs. The company has received substantial funding, with the last reported amount being over $86 billion in 2018, indicating strong investor confidence in their mission and capabilities.

4. Pfizer 21

• Website: pfizer.dk
• Ownership type: Private
• Headquarters: Manchester Township, New Jersey, United States (USA)
• Employee distribution: India 74%, Saudi Arabia 26%
• Founded year: 1998
• Headcount: 5001-10000
• LinkedIn: pfizer-21

Pfizer 21, based in Manchester Township, New Jersey, is a private biopharmaceutical company that specializes in the research, development, and manufacturing of innovative medications and treatments. Founded in 1998, the company has a workforce of approximately 23 employees, with a significant portion of its operations based in India and Saudi Arabia. Pfizer 21 is dedicated to enhancing patient care by collaborating with healthcare providers and organizations. They conduct extensive clinical research aimed at improving health outcomes and have a broad portfolio of prescription medications. The company emphasizes the importance of innovation, investing heavily in research to develop new treatment options. Their commitment to ethical practices and transparency in collaboration with healthcare professionals further underscores their role in the biopharmaceutical industry.

5. Elevar Therapeutics

• Website: elevartherapeutics.com
• Ownership type: Private
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: United States (USA) 92%, Germany 8%
• Latest funding: $20.0M, July 2018
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: elevartherapeutics

Elevar Therapeutics, founded in 2019 and based in Fort Lee, New Jersey, is a private biopharmaceutical company dedicated to developing innovative therapies for oncology. With a workforce of around 60 employees, the company is focused on addressing the needs of patients who have limited or inadequate therapeutic options. Their key products include Rivoceranib, a small-molecule tyrosine kinase inhibitor, and Camrelizumab, a monoclonal antibody targeting the PD-1 receptor. Elevar is actively engaged in clinical research, as evidenced by their participation in the upcoming 2024 ASCO Annual Meeting, where they will present findings from their studies. The company aims to set new standards of care and improve treatment experiences for patients, reflecting a strong commitment to advancing oncology care.

6. CSL Seqirus

• Website: cslseqirus.com
• Ownership type: Private
• Headquarters: Summit, New Jersey, United States (USA)
• Employee distribution: United States (USA) 42%, Netherlands 21%, United Kingdom (UK) 21%, Other 16%
• Founded year: 1916
• Headcount: 1001-5000
• LinkedIn: cslseqirus

CSL Seqirus, a subsidiary of CSL Limited, is a biotechnology and pharmaceutical company based in Summit, New Jersey. Founded in 1916, the company specializes in the development and manufacturing of vaccines and therapies aimed at treating rare and serious diseases. With a workforce of approximately 2,643 employees, CSL Seqirus operates on a global scale, contributing significantly to public health through its innovative medical solutions. The company is recognized as one of the largest providers of influenza vaccines worldwide, playing a crucial role in pandemic response and vaccination efforts. Their research and development focus includes advanced vaccine technology and a commitment to improving health outcomes for patients. CSL Seqirus is dedicated to quality and safety, ensuring compliance with global regulatory standards throughout the product lifecycle. Their operations reflect a strong emphasis on patient health and community support, making them a relevant entity in the biopharmaceutical industry.

7. Janssen Research & Development, LLC

• Website: janssenrnd.com
• Ownership type: Private
• Headquarters: Raritan, New Jersey, United States (USA)
• Employee distribution: United States (USA) 89%, Belgium 3%, Poland 3%, Other 5%
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: janssen-research-%26-development-llc

Janssen Research & Development, LLC, based in Raritan, New Jersey, is a pharmaceutical company that specializes in creating innovative medicines. Founded in 2001, the company is dedicated to developing treatments for serious health conditions across various therapeutic areas, including oncology, immunology, and neuroscience. Janssen serves healthcare professionals and patients by providing access to advanced medical therapies and solutions. With a workforce of over 1,000 employees, the company is primarily located in the United States, with a small presence in Belgium, Poland, China, and the United Kingdom. Janssen is known for its robust research and development efforts, having invested significantly in R&D to bring transformative therapies to market. Their product pipeline includes a range of medications that address complex diseases, showcasing their commitment to improving patient outcomes.

8. Celltrion USA

• Website: celltrionusa.com
• Ownership type: Private
• Headquarters: Jersey City, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: celltrionusa

Celltrion USA, Inc. is a biopharmaceutical company based in Jersey City, New Jersey, established in 2018. The company is dedicated to enhancing patient access to high-quality biologics, which are critical in treating a range of diseases. With a workforce of approximately 93 employees, Celltrion USA leverages its biotechnology heritage to provide advanced therapies within the U.S. healthcare system. Their product offerings include Zymfentra™, Yuflyma®, and Vegzelma®, which are designed to meet the needs of patients requiring biologic treatments. The company emphasizes its commitment to patient welfare and strives to improve healthcare access through its innovative solutions.

9. Mitsubishi Tanabe Pharma America

• Website: mt-pharma-america.com
• Ownership type: Private
• Headquarters: Jersey City, New Jersey, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: mitsubishi-tanabe-pharma-america

Mitsubishi Tanabe Pharma America, founded in 2016 and based in Jersey City, New Jersey, is a pharmaceutical company dedicated to developing innovative treatments for serious diseases, particularly amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The company is part of a long-standing legacy of medical advancements, with its parent company, Mitsubishi Tanabe Pharma Corporation, having over 300 years of experience in the pharmaceutical industry. Mitsubishi Tanabe Pharma America focuses on research and development to create effective therapeutic options that address significant unmet medical needs. Their pipeline includes investigational treatments and they actively participate in clinical trials to advance their understanding of complex diseases. The company emphasizes a patient-centered approach, aiming to make a meaningful difference in the lives of those affected by debilitating conditions.

10. Anima Biotech

• Website: animabiotech.com
• Ownership type: Corporate
• Headquarters: Bernardsville, New Jersey, United States (USA)
• Employee distribution: Israel 74%, United Arab Emirates 23%, United Kingdom (UK) 3%
• Latest funding: $120.0M, March 2021
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: anima-biotech

Anima Biotech, founded in 2014 and based in Bernardsville, New Jersey, is a biotechnology firm that specializes in the development of small molecule mRNA drugs. The company leverages artificial intelligence to enhance drug discovery, particularly through its mRNA Lightning™ platform. This platform has generated over 2 billion images of the mRNA life cycle, allowing for advanced analysis and understanding of mRNA regulatory pathways. Anima's pipeline includes candidates in immunology, oncology, and neuroscience, with ongoing preclinical programs targeting conditions such as lung fibrosis, solid tumors, and Alzheimer's disease. The company collaborates with prominent pharmaceutical partners, including Lilly, Takeda, and AbbVie, to explore new therapeutic avenues and optimize drug development processes. Anima Biotech's focus on mRNA biology and its innovative use of AI technology position it as a significant player in the biopharmaceutical sector.

11. Venenum BioDesign, LLC

• Website: venenumbiodesign.com
• Ownership type: Private
• Headquarters: Hamilton Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: venenum-biodesign-llc

Venenum BioDesign, LLC, based in Hamilton Township, New Jersey, is a biotechnology firm founded in 2009. The company is dedicated to drug discovery and development, with a particular emphasis on addressing unmet medical needs in immuno-oncology and metabolic diseases. Venenum BioDesign operates with a mission to improve patient outcomes through innovative therapeutic compounds. Their scientific team, composed of experienced biologists and chemists, utilizes proprietary technologies and a substantial collection of small molecules to identify and optimize drug candidates. They engage in partnerships for clinical and commercial development, showcasing their commitment to bringing new medicines to market. As a member of the Genesis Biotechnology Group, Venenum BioDesign collaborates with other entities to enhance their drug discovery capabilities, making them a relevant player in the biopharmaceutical industry.

12. Cornerstone Pharmaceuticals

• Website: cornerstonepharma.com
• Ownership type: Private
• Headquarters: Cranbury, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2001
• Headcount: 11-50
• LinkedIn: cornerstonepharma

Cornerstone Pharmaceuticals, based in Cranbury, New Jersey, is a private pharmaceutical company that specializes in developing innovative therapies for cancer. Founded in 2001, the company is dedicated to addressing significant unmet medical needs in oncology, particularly for hard-to-treat cancers. Their lead compounds, CPI-613® (devimistat) and CB-839 (telaglenastat), are currently undergoing multiple clinical trials aimed at evaluating their effectiveness against various malignancies, including pancreatic cancer and biliary tract cancer. Cornerstone's research is grounded in metabolic science, focusing on disrupting the energy production of cancer cells while harnessing the immune system's potential. The company has received orphan drug designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for devimistat, underscoring its commitment to advancing treatment options for patients with rare cancers. With a team of experienced professionals and advisors from prestigious institutions, Cornerstone Pharmaceuticals is actively contributing to the field of oncology through its research and clinical initiatives.

13. NS Pharma, Inc.

• Website: nspharma.com
• Ownership type: Private
• Headquarters: Paramus, New Jersey, United States (USA)
• Employee distribution: United States (USA) 95%, Ghana 4%, Other 2%
• Founded year: 1999
• Headcount: 51-200
• LinkedIn: ns-pharma-inc

NS Pharma, Inc., based in Paramus, New Jersey, is a private biopharmaceutical company founded in 1999. The company specializes in developing therapies for rare diseases, with a particular emphasis on Duchenne muscular dystrophy (DMD). NS Pharma is known for its innovative approach to exon-skipping technology, which aims to enhance patient outcomes for those affected by DMD. Their flagship product, VILTEPSO (viltolarsen), received accelerated approval from the FDA in 2020, marking a significant milestone in their efforts to provide effective treatment options. The company is dedicated to conducting rigorous clinical research and has a pipeline that includes several investigational therapies targeting DMD and other rare conditions. NS Pharma operates with a strong commitment to patient care and community support, collaborating with advocacy organizations to facilitate access to their therapies.

14. Acrotech Biopharma Inc

• Website: acrotechbiopharma.com
• Ownership type: Private
• Headquarters: East Windsor, New Jersey, United States (USA)
• Employee distribution: United States (USA) 96%, India 4%
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: acrotech-biopharma

Acrotech Biopharma Inc, based in East Windsor, New Jersey, is a private pharmaceutical company established in 2018. The firm is dedicated to developing and commercializing innovative proprietary medications, with a strong emphasis on oncology. Acrotech aims to address significant unmet medical needs by providing scientifically advanced products that deliver value to patients and healthcare providers alike. Their product portfolio includes treatments like HEMADY, indicated for multiple myeloma, and EVOMELA, a formulation of melphalan. The company is focused on building collaborations to enhance its expertise in small molecules and biologics, striving to create breakthrough therapies that can change treatment paradigms. With a workforce of around 53 employees, Acrotech is actively working to expand its commercial infrastructure to maximize the potential of its current and future products.

15. TAXIS Pharmaceuticals, Inc.

• Website: taxispharma.com
• Ownership type: Private
• Headquarters: South Brunswick Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.7M, May 2024
• Founded year: 2009
• Headcount: 1-10
• LinkedIn: taxis-pharmaceuticals-inc.

TAXIS Pharmaceuticals, Inc. is a private biopharmaceutical company based in South Brunswick Township, New Jersey, founded in 2009. The company is dedicated to combating antimicrobial resistance through innovative drug development. Their research focuses on creating therapies specifically designed to tackle antibiotic-resistant infections, which are increasingly prevalent in healthcare settings. TAXIS Pharmaceuticals is actively engaged in research and development aimed at restoring the efficacy of antibiotics and addressing critical health challenges associated with resistant bacteria. Their pipeline includes investigational therapeutics such as TXA709, an oral anti-MRSA agent, and various efflux pump inhibitors aimed at enhancing the effectiveness of existing antibiotics. Recently, they secured a $2.67 million grant from the NIH to advance their research on combination therapies for antibiotic-resistant pneumonia, underscoring their active role in the biopharmaceutical industry.

16. Kedrion Biopharma US

• Website: kedrion.us
• Ownership type: Family Owned
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Founded year: 2011
• Headcount: 1001-5000
• LinkedIn: bio-products-laboratory-usa-inc.

Kedrion Biopharma US, based in Fort Lee, New Jersey, is a family-owned biopharmaceutical company that was founded in 2011. The company specializes in the production and distribution of plasma-derived therapeutic products aimed at treating serious conditions such as hemophilia and primary immune deficiencies. Kedrion operates with a strong emphasis on quality and safety, ensuring that their products meet rigorous standards. Their activities span from plasma collection to product development, clinical operations, and pharmacovigilance, reflecting a comprehensive approach to healthcare. Kedrion has established a significant presence in approximately 100 countries, showcasing their commitment to global health. They also engage in community support initiatives, reinforcing their role as a responsible corporate citizen in the healthcare sector.

17. Octapharma USA, Inc.

• Website: octapharmausa.com
• Ownership type: Private
• Headquarters: Paramus, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2003
• Headcount: 51-200
• LinkedIn: octapharma-usa

Octapharma USA, Inc., founded in 2003 and based in Paramus, New Jersey, is a private healthcare company that specializes in the development and manufacturing of plasma-derived therapies. The company is part of the larger Octapharma Group, which is recognized as the largest privately owned and independent plasma fractionator globally. Octapharma USA focuses on creating essential medicines for patients suffering from bleeding disorders, immune deficiencies, and those in critical care situations. Their operations include the collection and processing of plasma, which is vital for producing high-quality therapeutic products. The company has established a strong presence in the industry, with a commitment to quality and safety throughout its production processes. Octapharma USA actively engages with the community and supports organizations that benefit patients reliant on their therapies. Their product portfolio includes treatments for rare diseases and coagulopathies, showcasing their dedication to addressing unmet medical needs.

18. Salix Pharmaceuticals

• Website: salix.com
• Ownership type: Corporate
• Headquarters: Bridgewater, New Jersey, United States (USA)
• Employee distribution: United States (USA) 99%
• Latest funding: February 2015
• Founded year: 1988
• Headcount: 501-1000
• LinkedIn: salix-pharmaceuticals

Salix Pharmaceuticals, founded in 1988 and based in Bridgewater, New Jersey, is a specialty pharmaceutical company dedicated to developing and marketing innovative treatments for gastrointestinal disorders. The company has a strong focus on chronic GI conditions, providing effective solutions for patients and healthcare professionals alike. Salix has a robust portfolio of products, including treatments for overt hepatic encephalopathy, irritable bowel syndrome, chronic idiopathic constipation, and ulcerative colitis. Their commitment to research and development is reflected in their promising pipeline of new therapies aimed at improving patient outcomes. Salix operates under the umbrella of Bausch Health Companies Inc., which enhances its capabilities and resources in the biopharmaceutical space. The company has not reported any recent funding, indicating stability and a focus on organic growth.

19. Mestastop Solutions

• Website: mestastop.com
• Ownership type: Venture Capital
• Headquarters: Evesham, New Jersey, United States (USA)
• Employee distribution: India 95%, Switzerland 5%
• Latest funding: Seed, $541,000, October 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: mestastop-solutions

Mestastop Solutions, founded in 2018 and based in Evesham, New Jersey, is a biotechnology firm dedicated to cancer research and treatment. The company specializes in addressing the complexities of cancer metastasis through innovative solutions in drug discovery, drug repurposing, and clinical translations. Their primary clientele includes healthcare providers and pharmaceutical companies seeking advanced research services to enhance cancer treatment outcomes. Mestastop has recently secured funding, which underscores investor confidence in their mission and capabilities. The company operates with a team of experts in biochemistry, cell biology, and predictive analytics, leveraging technology to develop effective solutions for cancer patients. Their proprietary platforms dissect metastasis biology, aiming to improve the understanding and treatment of this critical aspect of cancer progression.

20. Prolong Pharmaceuticals

• Website: prolongpharma.com
• Ownership type: Venture Capital
• Headquarters: South Plainfield, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $30.0M, October 2010
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: prolong-pharmaceuticals

Prolong Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company based in South Plainfield, New Jersey. Founded in 2005, the company is dedicated to identifying, developing, and commercializing innovative therapeutics aimed at treating complex diseases and addressing unmet medical needs. Prolong specializes in conditions such as ischemia, hypoxia, sickle cell disease, and cystic fibrosis. Their flagship product, PP-007 (Sanguinate®), is a PEGylated carboxyhemoglobin designed to improve oxygen delivery in hypoxic tissues. The company has completed 12 clinical trials involving over 250 individuals, demonstrating their commitment to advancing treatment options. Prolong's founders were instrumental in the development of PEGylation technology, which has significantly impacted drug delivery systems. With a focus on clinical research and a strong pipeline, Prolong Pharmaceuticals is positioned as a relevant player in the biopharmaceutical industry.

21. Antares Pharma Inc.

• Website: antarespharma.com
• Ownership type: Corporate
• Headquarters: Ewing Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $960.0M, April 2022
• Founded year: 1979
• Headcount: 51-200
• LinkedIn: antares-pharma-inc-

Antares Pharma Inc. is a biotechnology firm based in Ewing Township, New Jersey, founded in 1979. The company focuses on innovative drug delivery technologies, particularly through its proprietary ENHANZE® platform, which facilitates rapid subcutaneous drug administration. This technology aims to improve patient experiences by reducing the time and complexity associated with traditional intravenous infusions. Antares Pharma also develops auto-injector and multi-dose pen technologies, showcasing their commitment to enhancing treatment options. The company has received significant funding, with a reported amount of $960 million in April 2022, indicating strong investor confidence in their potential to impact the biopharmaceutical industry. Their commercial products include FDA-approved therapies that leverage their unique drug delivery technologies, further solidifying their role in the market.

22. ContraVir Pharmaceuticals, Inc.

• Website: contravir.com
• Ownership type: Private
• Headquarters: Edison, New Jersey, United States (USA)
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: contravir-pharmaceuticals-inc-

ContraVir Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Edison, New Jersey. Founded in 2013, the company is dedicated to developing innovative therapies for chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Their lead drug candidate, rencofilstat, is designed to target multiple mechanisms involved in liver disease, showcasing a unique approach to treatment. The company employs advanced artificial intelligence techniques through its AI-POWR™ platform, which enhances drug development processes and aims to improve patient outcomes. This focus on AI-driven methodologies not only streamlines their research but also positions them to better understand and address the complexities of liver diseases. As they continue to advance their clinical trials, ContraVir remains committed to providing effective treatment options for patients suffering from these serious conditions.

23. ForDoz Pharma Corp

• Website: fordozpharma.com
• Ownership type: Private
• Headquarters: East Windsor, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: fordoz-pharma-corp

ForDoz Pharma Corp is an innovative pharmaceutical company based in East Windsor, New Jersey, specializing in the development, manufacturing, and commercialization of complex injectable products. Established in 2014, ForDoz aims to address significant unmet medical needs for patients suffering from severe and chronic diseases. The company has developed proprietary particle-based drug delivery technology platforms, which have led to a robust pipeline of both generic and innovative complex injectable products. In July 2024, ForDoz received FDA approval for its first product, Doxorubicin Hydrochloride Liposome Injection, which was launched in the U.S. market shortly thereafter. The company operates a state-of-the-art cGMP sterile manufacturing facility dedicated to producing these complex injectables. Additionally, ForDoz offers Contract Development and Manufacturing Organization (CDMO) services, assisting other pharmaceutical companies in developing and manufacturing their injectable products. With a focus on innovation and quality, ForDoz Pharma is positioned to make a significant impact in the biopharmaceutical industry.

Biopharmaceuticals Insights: Key Companies in New Jersey

Want to Find More Biopharmaceuticals Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!